The blood-based genomic profiling assay for advanced solid tumors is now reimbursable under Medicare’s policy covering plasma-based genomic profiling tests.
NeoGenomics has secured Medicare coverage for its PanTracer LBx test, a blood-based genomic profiling tool designed to guide therapy selection and clinical trial enrollment in patients with advanced solid tumors.
The Centers for Medicare & Medicaid Services (CMS) Molecular Diagnostics Services Program (MolDX) granted coverage for PanTracer LBx under LCD – MolDX: Plasma-Based Genomic Profiling in Solid Tumors (L38043). The test is performed in NeoGenomics’ Clinical Laboratory Improvement Amendments-certified laboratory in California.
“Securing Medicare coverage for PanTracer LBx represents a significant milestone in making precision oncology more accessible, particularly for those choosing treatment in the community setting,” says Tony Zook, chief executive officer of NeoGenomics, in a release. “This coverage decision reinforces the clinical value of liquid biopsy and enables physicians to deliver timely, personalized treatment strategies for their patients.”
What the Test Evaluates
PanTracer LBx analyzes a blood sample to generate actionable biomarker data, evaluating more than 500 genes, including microsatellite instability and blood-based tumor mutational burden (bTMB), according to NeoGenomics. The test has a seven-day turnaround time.
Clinicians can order PanTracer LBx as a standalone test, as a reflex option when tissue sample quantity is insufficient for standard profiling, or concurrently alongside tissue-based analysis—offering flexibility depending on the clinical scenario.
Part of a Broader Portfolio
PanTracer LBx is one component of NeoGenomics’ PanTracer portfolio, which also includes PanTracer Tissue, a tissue-based genomic profiling test. Together, the two tests are intended to support pan-solid tumor profiling across different care settings, according to the company.
The CMS coverage decision extends access to the liquid biopsy test for Medicare patients, who previously may not have had reimbursement coverage for the noninvasive genomic test, the company says in a release.
ID 33572616 | Health © Tashatuvango | Dreamstime.com
Related Reading:
Illumina Secures CMS Reimbursement for TruSight Oncology Test
Three-Year NHS Study Shows Blood Test Reduces Stage IV Cancer Diagnoses
Labcorp Acquires BioReference Health’s Oncology Testing Assets for $225 Million
